AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27758992
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of positive Xpert MTB/RIF, positive tuberculin skin test, heterogeneous echotexture of lymph nodes, or endosonographic coagulation necrosis sign
Trial: 23242731
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% caudally (0.5 ml/kg)
Trial: 23242731
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% caudally (0.5 ml/kg)
Trial: 8903817
Drug: Sulfate-free polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfate-free polyethylene glycol electrolyte lavage solution (SF-PEG-ELS)
Trial: 8140562
Drug: Selegiline (S)
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selegiline (S) 10 mg/day
Trial: 27602665
Drug: Adalimumab (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (loading dose of 80 mg followed by 40 mg every 2 weeks)
Trial: 17274828
Drug: CORE (1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORE (1028 mg daily)
Trial: 16227771
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy initiated in-hospital
Trial: 7888977
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch treatment (16 hours per day for 18 weeks)
Trial: 7888977
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch treatment
Trial: 7888977
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch treatment with gradual reduction
Trial: 7888977
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch treatment with dose increase after week 1
Trial: 2198812
Drug: 0.5% betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% betaxolol ophthalmic solution
Trial: 857138
Drug: 300 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/die Allopurinol
Trial: 857138
Drug: 100 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/die Benzbromarone
Trial: 857138
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Allopurinol with 20 mg Benzbromarone
Trial: 30924163
Drug: EA-230 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA-230 (90 mg/kg/hour for 2 hours)
Trial: 30924163
Drug: EA-230 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA-230 (1, 3, 10, or 30 mg/kg single dosage)
Trial: 30924163
Drug: EA-230 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA-230 (10, 20, or 30 mg/kg, thrice daily for 3 days)
Trial: 30924163
Drug: EA-230 (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA-230 (15, 30, or 90 mg/kg/hour for 2 hours)
Trial: 29354954
Drug: No.1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No.1 treatment group (ginger-prepared paste)
Trial: 29354954
Drug: No.2 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No.2 treatment group (honey-prepared paste)
Trial: 29354954
Drug: No.3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No.3 treatment group (honey-prepared paste, 6h application)
Trial: 20544178
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of calcium and 400 IU of vitamin D3
Trial: 15380859
Drug: Olanzapine, 5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine, 5-20 mg/day for 8 months
Trial: 2491707
Drug: Cefuroxime-axetil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime-axetil (250 mg twice daily after meal)
Trial: 2491707
Drug: Cefadroxil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil (1 g twice daily during meal)
Trial: 31745044
Drug: Phonophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis with aceclofenac gel
Trial: 23636029
Drug: Reflexology therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology therapy (AEDs + reflexology therapy)
Trial: 12101597
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (Control)
Trial: 20029710
Drug: Greater AD
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater AD treatment optimism
Trial: 16484699
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg/d orally, escalated to 400 mg/d)
Trial: 16484699
Drug: Medroxyprogesterone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone (300 mg orally daily)
Trial: 7034641
Drug: Ceforanide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceforanide (0.5 g every 12 h)
Trial: 7034641
Drug: Cefazolin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1.0 g every 8 h)
Trial: 29045315
Drug: ATP supplementation
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP supplementation (400 mg)
Trial: 27696395
Drug: Nab-paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel at a dose of 175 mg/m2 plus nedaplatin at a dose of 80 mg/m2 administered intravenously every 3 weeks
Trial: 8534461
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac IV
Trial: 8534461
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac IM
Trial: 2725118
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine system (TNS) 10, 20, and 40 mg/24 h
Trial: 2725118
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine system (TNS) delivering 14 mg nicotine/24 h
Trial: 4902196
Drug: Protein-free liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-free liver extract (Ripason) administered both orally and intramuscularly
Trial: 24937390
Drug: Double-modality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-modality therapy (DMT) - cryotherapy and 15% methyl salicylate phonophoresis
Trial: 24937390
Drug: Double-modality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-modality therapy (DMT)
Trial: 21689019
Drug: Formoterol by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol by pressurized metered-dose inhaler (pMDI) 12 μg b.i.d.
Trial: 21689019
Drug: Formoterol by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol by dry powder inhaler (DPI) 12 μg b.i.d.
Trial: 18687132
Drug: Intravenous antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antioxidant supplements (selenium 270 microg, zinc 30 mg, vitamin C 1.1 g, and vitamin B1 100 mg) for 5 days with a double-loading dose on days 1 and 2
Trial: 18687132
Drug: Intravenous antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antioxidant supplements
Trial: 12631424
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sumatriptan orally
Trial: 9850897
Drug: 3 drops
RxNorm normalized name: UpSpring WellBaby DHA + Vitamin D3 Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 drops of lidocaine 4% plus intracameral injection of 0.1 mL lidocaine 1%
Trial: 2531908
Drug: Polyvalent melanoma
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent melanoma cell vaccine alone
Trial: 2531908
Drug: Polyvalent melanoma
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent melanoma cell vaccine with low-dose cyclophosphamide
Trial: 2531908
Drug: Other immunomodulators
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other immunomodulators (alone or in combination with lower doses of cyclophosphamide)
Trial: 11711455
Drug: Intervention trials
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention trials on treatment of acute myocardial infarction
Trial: 31075706
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), 12 sessions
Trial: 29438425
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid ointment
Trial: 11782569
Drug: Cisapride, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 20 mg b.i.d., during 4 weeks
Trial: 10095800
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin daily for 6 weeks, followed by 80 mg atorvastatin for another 6 weeks
Trial: 10095800
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin alone
Trial: 10095800
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin with 8-12 g colestyramin
Trial: 10095800
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin with 1800 mg nicotinic acid
Trial: 29500292
Drug: Intravenous elamipretide
RxNorm normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous elamipretide (0.25 mg/kg/h)
Trial: 29500292
Drug: Intravenous elamipretide
RxNorm normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous elamipretide (highest dose)
Trial: 21676990
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 10 weeks
Trial: 21676990
Drug: Clinical monitoring
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical monitoring (no new treatment)
Trial: 17579653
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) group (n=38)
Trial: 12824815
Drug: 21‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg nicotine patch
Trial: 10873077
Drug: i.p. recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.p. recombinant IFN-gamma (rIFN-gamma) and higher rIL-2 dosing (group A)
Trial: 10873077
Drug: i.p. recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.p. recombinant IFN-gamma (rIFN-gamma) and lower rIL-2 dosing (group B)
Trial: 8879704
Drug: Sodium clodronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium clodronate, total daily dose of 1600‐3200 mg
Trial: 6229564
Drug: Trazodone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (300 mg mean maintenance dosage, range 200-350 mg)
Trial: 6229564
Drug: Imipramine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (160 mg mean maintenance dosage, range 150-175 mg)
Trial: 31107560
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lidocaine‐and‐prilocaine (LP) cream for 120 minutes
Trial: 26848561
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg twice daily added to subcutaneous interferon β‐1a therapy
Trial: 26848561
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to subcutaneous interferon β‐1a therapy
Trial: 18974025
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 7 days (Group A)
Trial: 18974025
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 10 days (Group B)
Trial: 18974025
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg b.d. for 7 days (Group C)
Trial: 18974025
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg b.d. for 10 days (Group D)
Trial: 18974025
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days treatment (Groups A and C)
Trial: 18974025
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days treatment (Groups B and D)
Trial: 18974025
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily levofloxacin (Group B)
Trial: 18974025
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily levofloxacin (Groups C and D)
Trial: 15854188
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg as needed
Trial: 11980623
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g testosterone gel daily for 10 days
Trial: 11980623
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g testosterone gel daily for 10 days
Trial: 11980623
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g testosterone gel with washing off after 10 min
Trial: 2032716
Drug: Interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha‐2b subcutaneously (s.c.) 5 x 10(6) IU three times weekly for four weeks
Trial: 7072623
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg riboflavin daily for 12 weeks
Trial: 24958479
Drug: Adalimumab (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (subcutaneous, every 2 weeks for 12 weeks)
Trial: 24958479
Drug: Placebo (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous, every 2 weeks for 12 weeks)
Trial: 22042703
Drug: Dexamethasone 0.3
RxNorm normalized name: dexamethasone 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.3 mg·kg(‐1)
Trial: 15695985
Drug: Oral mifepristone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mifepristone (200 mg, administered orally)
Trial: 15695985
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (infusion)
Trial: 8507025
Drug: 4.4 mL
RxNorm normalized name: APONVIE 32 MG in 4.4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 mL of 2% lidocaine with 1:80,000 epinephrine
Trial: 8507025
Drug: 4.4 mL
RxNorm normalized name: APONVIE 32 MG in 4.4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 mL of 3% prilocaine with 0.03 IU/mL felypressin
Trial: 3908331
Drug: Acebutolol (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (100-400 mg)
Trial: 3908331
Drug: Propranolol (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-160 mg)
Trial: 3543146
Drug: Intravenous chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous chloroquine
Trial: 3543146
Drug: Subcutaneous chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous chloroquine
Trial: 27097693
Drug: Oral chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloroquine
Trial: 20557362
Drug: PPI-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based triple therapy plus S. boulardii for 4 weeks
Trial: 20557362
Drug: PPI-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based triple therapy plus S. boulardii and DA-9601 for 4 weeks
Trial: 20557362
Drug: PPI-based 7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based 7-day triple therapy
Trial: 16151466
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD-AraC) alone (2 x 10 mg/m2/day subcutaneously days 1-14)
Trial: 16151466
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD-AraC) plus granulocyte/macrophage colony stimulating factor (rhGM-CSF) (150 microg/day s.c. from day 8 to 21)
Trial: 16151466
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD-AraC) plus Interleukin-3 (IL-3) (150 microg/day s.c. from day 8 to 21)
Trial: 16151466
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD-AraC) with GM-CSF or IL-3
Trial: 9370836
Drug: Morphine patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine patient-controlled analgesia
Trial: 1606996
Drug: Oxazepam 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 7.5 mg
Trial: 1606996
Drug: Oxazepam 35
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam 35 mg
Trial: 1606996
Drug: Oxazepam 45
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam 45 mg
Trial: 1606996
Drug: Oxazepam 50
RxNorm normalized name: oxazepam 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 50 mg
Trial: 3896566
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily beclomethasone dipropionate (BDP)
Trial: 3896566
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily beclomethasone dipropionate (BDP)
Trial: 30796818
Drug: Ad26.ZEBOV dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV dose 1
Trial: 29473247
Drug: D-methionine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-methionine (100 mg/kg p.o. b.i.d.)
Trial: 24249842
Drug: 12-week exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week exercise programme including group exercise training twice a week and daily walks
Trial: 22067197
Drug: Food intake
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food intake (standard breakfast 30 to 10 minutes prior to dosing)
Trial: 22067197
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (400 mg of moxifloxacin)
Trial: 16105374
Drug: Enhanced occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced occupational therapy support intervention
Trial: 10902449
Drug: 5% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% prilocaine (1 mg/kg, n = 27)
Trial: 10902449
Drug: 2% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mepivacaine (0.8 mg/kg, n = 30)
Trial: 9398880
Drug: LAC1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC1 (1 week of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Trial: 9398880
Drug: LAC2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC2 (2 weeks of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Trial: 7979622
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg three times a day)
Trial: 3891188
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg a day)
Trial: 28343051
Drug: Cariprazine 3–6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 3–6 mg/d
Trial: 28343051
Drug: Cariprazine 9–12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 9–12 mg/d
Trial: 18992854
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,800 mg
Trial: 3102585
Drug: Verapamil SR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR, 360 mg